Clinical Research Directory
Browse clinical research sites, groups, and studies.
An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant
Sponsor: Regeneron Pharmaceuticals
Summary
The main purpose of this study is to continue to see how vonsetamig works in the body and to monitor the outcomes after kidney transplant for participants previously treated in the R5459-RT-1944 study (NCT05092347). No study drug will be given during this study.
Official title: A Noninterventional Extension Study for Patients Treated in Study R5459-RT-1944 With Vonsetamig (BCMA x CD3 Bispecific Antibody) Who Receive a Kidney Transplant
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
OBSERVATIONAL
Enrollment
20
Start Date
2023-10-19
Completion Date
2027-12-24
Last Updated
2025-06-22
Healthy Volunteers
No
Conditions
Interventions
Noninterventional
No investigational treatment will be given in this noninterventional extension study
Locations (9)
Cedars-Sinai Medical Center
Los Angeles, California, United States
University of California Irvine
Orange, California, United States
Connie Frank Transplant Center at UCSF
San Francisco, California, United States
Yale University of Medicine
New Haven, Connecticut, United States
Comprehensive Transplant Center
Chicago, Illinois, United States
John Hopkins Hospital
Baltimore, Maryland, United States
University of Minnesota
Minneapolis, Minnesota, United States
New York University Langone Health
New York, New York, United States
Penn Transplant Institute
Philadelphia, Pennsylvania, United States